Lung stereotactic body radiotherapy with an MR-linac - Quantifying the impact of the magnetic field and real-time tumor tracking
Author(s)
Type
Journal Article
Abstract
Background and purpose
There are concerns that radiotherapy doses delivered in a magnetic field might be distorted due to the Lorentz force deflecting secondary electrons. This study investigates this effect on lung stereotactic body radiotherapy (SBRT) treatments, conducted either with or without multileaf collimator (MLC) tumor tracking.
Material and methods
Lung SBRT treatments with an MR-linac were simulated for nine patients. Two different treatment techniques were compared: conventional, non-tracked deliveries and deliveries with real-time MLC tumor tracking, each conducted either with or without a 1.5 T magnetic field.
Results
Slight dose distortions at air-tissue-interfaces were observed in the presence of the magnetic field. Most prominently, the dose to 2% of the skin increased by 1.4 Gy on average. Regardless of the presence of the magnetic field, MLC tracking was able to spare healthy tissue, for example by decreasing the mean lung dose by 0.3 Gy on average, while maintaining the target dose.
Conclusions
Accounting for the magnetic field during treatment plan optimization allowed for design and delivery of clinically acceptable lung SBRT treatments with an MR-linac. Furthermore, the ability of MLC tumor tracking to decrease dose exposure of healthy tissue, was not inhibited by the magnetic field.
There are concerns that radiotherapy doses delivered in a magnetic field might be distorted due to the Lorentz force deflecting secondary electrons. This study investigates this effect on lung stereotactic body radiotherapy (SBRT) treatments, conducted either with or without multileaf collimator (MLC) tumor tracking.
Material and methods
Lung SBRT treatments with an MR-linac were simulated for nine patients. Two different treatment techniques were compared: conventional, non-tracked deliveries and deliveries with real-time MLC tumor tracking, each conducted either with or without a 1.5 T magnetic field.
Results
Slight dose distortions at air-tissue-interfaces were observed in the presence of the magnetic field. Most prominently, the dose to 2% of the skin increased by 1.4 Gy on average. Regardless of the presence of the magnetic field, MLC tracking was able to spare healthy tissue, for example by decreasing the mean lung dose by 0.3 Gy on average, while maintaining the target dose.
Conclusions
Accounting for the magnetic field during treatment plan optimization allowed for design and delivery of clinically acceptable lung SBRT treatments with an MR-linac. Furthermore, the ability of MLC tumor tracking to decrease dose exposure of healthy tissue, was not inhibited by the magnetic field.
Date Issued
2016-06-01
Date Acceptance
2016-04-11
Citation
Radiotherapy and Oncology, 2016, 119 (3), pp.461-466
ISSN
0167-8140
Publisher
Elsevier
Start Page
461
End Page
466
Journal / Book Title
Radiotherapy and Oncology
Volume
119
Issue
3
Copyright Statement
© 2016 The Author(s). Published by Elsevier Ireland Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380075400014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
Radiology, Nuclear Medicine & Medical Imaging
MR-linac
MR-guided radiotherapy
Real-time adaptive radiotherapy
Tumor tracking
Lung stereotactic body radiotherapy
PROOF-OF-CONCEPT
DOSE RECONSTRUCTION
RESPIRATORY MOTION
SYSTEM
MLC
FEASIBILITY
ACCELERATOR
COMPENSATION
DELIVERY
THERAPY
Publication Status
Published
Date Publish Online
2016-05-08